Middletown, Delaware - Datwylers Sealing Solutions has opened a new production plant for pharmaceutical components in Middletown, Delaware.
The CHF100-million (€88.1 million) production facility, said the Swiss company in a 28-Sept statement, operates to Datwyler’s ‘first line’ standard, based on advanced cleanroom technology, automated production, camera inspection and special cleaning processes.
Products include high-quality elastomer components for the growing biotech and pharmaceutical markets. The company expects to carry out certification by customers in the fourth quarter of 2018 and start series production at the beginning of 2019.
The facility is set to strengthens Datwyler's position in the US, which the company described as "the world's largest pharmaceutical market."
The added capacity will increase Datwayler’s global ‘first line’ volume by 50% by 2020.
Datwyler has recently expanded pharmaceutical components production at its Satara site in Pune, India, with the addition of a ‘first line’ production unit.
The company announced in June that the first commercial samples from the new Indian facility would be available in September.